Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Wailoo

Showing results (51-60 of 64) with videos related to

Pageof 7
Sort By:
Health Technology Assessment (Winchester, England)|December 6, 2017
The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysisAllan Wailoo, Emma S Hock, Matt Stevenson, et al.
Trials|December 10, 2017
Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trialNaomi H Martin, Fowzia Ibrahim, Brian Tom, et al.
Rheumatology and Therapy|October 18, 2016
Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working PartyJason Madan, Tony Ades, Pelham Barton, et al.
Health Technology Assessment (Winchester, England)|December 7, 2016
Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluationMatt Stevenson, Rachel Archer, Jon Tosh, et al.
Health Technology Assessment (Winchester, England)|May 4, 2016
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluationMatt Stevenson, Rachel Archer, Jon Tosh, et al.
Lancet (London, England)|December 19, 2016
Use of MRI in the diagnosis of fetal brain abnormalities in utero (MERIDIAN): a multicentre, prospective cohort studyPaul D Griffiths, Michael Bradburn, Michael J Campbell, et al.
BMC Geriatrics|February 11, 2026
A randomised controlled trial of Acceptance and Commitment Therapy plus usual care in comparison to usual care alone for reducing anxiety in older people with treatment-resistant generalised anxiety disorder (CONTACT-GAD): trial protocolRebecca L Gould, Tia Callaghan, David White, et al.
Health Technology Assessment (Winchester, England)|September 21, 2019
MRI in the diagnosis of fetal developmental brain abnormalities: the MERIDIAN diagnostic accuracy studyPaul D Griffiths, Michael Bradburn, Michael J Campbell, et al.
Seminars in Arthritis and Rheumatism|September 15, 2020
The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trialDavid Scott, Fowzia Ibrahim, Harry Hill, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 22, 2019
Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTAFinn Børlum Kristensen, Don Husereau, Mirjana Huić, et al.
Pageof 7

Showing results (51-60 of 64) with videos related to

Sort By:
Pageof 7
Health Technology Assessment (Winchester, England)|December 6, 2017
The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysisAllan Wailoo, Emma S Hock, Matt Stevenson, et al.
Trials|December 10, 2017
Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trialNaomi H Martin, Fowzia Ibrahim, Brian Tom, et al.
Rheumatology and Therapy|October 18, 2016
Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working PartyJason Madan, Tony Ades, Pelham Barton, et al.
Health Technology Assessment (Winchester, England)|December 7, 2016
Corrigendum: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluationMatt Stevenson, Rachel Archer, Jon Tosh, et al.
Health Technology Assessment (Winchester, England)|May 4, 2016
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluationMatt Stevenson, Rachel Archer, Jon Tosh, et al.
Lancet (London, England)|December 19, 2016
Use of MRI in the diagnosis of fetal brain abnormalities in utero (MERIDIAN): a multicentre, prospective cohort studyPaul D Griffiths, Michael Bradburn, Michael J Campbell, et al.
BMC Geriatrics|February 11, 2026
A randomised controlled trial of Acceptance and Commitment Therapy plus usual care in comparison to usual care alone for reducing anxiety in older people with treatment-resistant generalised anxiety disorder (CONTACT-GAD): trial protocolRebecca L Gould, Tia Callaghan, David White, et al.
Health Technology Assessment (Winchester, England)|September 21, 2019
MRI in the diagnosis of fetal developmental brain abnormalities: the MERIDIAN diagnostic accuracy studyPaul D Griffiths, Michael Bradburn, Michael J Campbell, et al.
Seminars in Arthritis and Rheumatism|September 15, 2020
The clinical effectiveness of intensive management in moderate established rheumatoid arthritis: The titrate trialDavid Scott, Fowzia Ibrahim, Harry Hill, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|January 22, 2019
Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTAFinn Børlum Kristensen, Don Husereau, Mirjana Huić, et al.
Pageof 7